| Ident. | Authors (with country if any) | Title |
|---|
| 000133 (2011) |
Brian Jeynes [Canada] ; John Provias [Canada] | The case for blood–brain barrier dysfunction in the pathogenesis of Alzheimer's disease |
| 000182 (2011) |
Natalie R. S. Goldberg [États-Unis] ; Tom Hampton [États-Unis] ; Scott Mccue [États-Unis] ; Ajit Kale [États-Unis] ; Charles K. Meshul [États-Unis] | Profiling changes in gait dynamics resulting from progressive 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine‐induced nigrostriatal lesioning |
| 000265 (2011) |
James A. Miller [États-Unis] ; Briana R. Trout [États-Unis] ; Kelly A. Sullivan [États-Unis] ; Russell A. Bialecki [États-Unis] ; Ruth A. Roberts [Royaume-Uni] ; Ronald B. Tjalkens [États-Unis] | Low‐dose 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine causes inflammatory activation of astrocytes in nuclear factor‐κB reporter mice prior to loss of dopaminergic neurons |
| 000565 (2010) |
Jonathan D. Verrier [États-Unis] ; Susan Semple-Rowland [États-Unis] ; Irina Madorsky [États-Unis] ; Joseph E. Papin [États-Unis] ; Lucia Notterpek [États-Unis] | Reduction of Dicer impairs Schwann cell differentiation and myelination |
| 000702 (2010) |
Aleksandra Glavaski-Joksimovic [États-Unis] ; Tamas Virag [États-Unis] ; Thomas A. Mangatu [États-Unis] ; Michael Mcgrogan [États-Unis] ; Xue Song Wang [États-Unis] ; Martha C. Bohn [États-Unis] | Glial cell line‐derived neurotrophic factor–secreting genetically modified human bone marrow‐derived mesenchymal stem cells promote recovery in a rat model of Parkinson's disease |
| 000731 (2010) |
Noriyuki Yamamoto [Japon] ; Yasuhiko Izumi [Japon] ; Takaaki Matsuo [Japon] ; Seiko Wakita [Japon] ; Toshiaki Kume [Japon] ; Yuki Takada-Takatori [Japon] ; Hideyuki Sawada [Japon] ; Akinori Akaike [Japon] | Elevation of heme oxygenase‐1 by proteasome inhibition affords dopaminergic neuroprotection |
| 000734 (2010) |
Ruth H. Walker [États-Unis] ; Georgia Davies [États-Unis] ; Rick J. Koch [États-Unis] ; Andrew K. Haack [États-Unis] ; Cynthia Moore [États-Unis] ; Charles K. Meshul [États-Unis] | Effects of zona incerta lesions on striatal neurochemistry and behavioral asymmetry in 6‐hydroxydopamine‐lesioned rats |
| 000951 (2009) |
Michaela Hahn [Allemagne] ; Marco Timmer [Allemagne] ; Guido Nikkhah [Allemagne] | Survival and early functional integration of dopaminergic progenitor cells following transplantation in a rat model of Parkinson's disease |
| 000956 (2009) |
Seung U. Kim [Canada, Corée du Sud] ; Jean De Vellis [États-Unis] | Stem cell‐based cell therapy in neurological diseases: A review |
| 000A14 (2009) |
Hiroki Takeuchi [Japon] ; Takashi Yanagida [Japon] ; Masatoshi Inden [Japon] ; Kazuyuki Takata [Japon] ; Yoshihisa Kitamura [Japon] ; Kentaro Yamakawa [Japon] ; Hideyuki Sawada [Japon] ; Yasuhiko Izumi [Japon] ; Noriyuki Yamamoto [Japon] ; Takeshi Kihara [Japon] ; Kengo Uemura [Japon] ; Haruhisa Inoue [Japon] ; Takashi Taniguchi [Japon] ; Akinori Akaike [Japon] ; Ryosuke Takahashi [Japon] ; Shun Shimohama [Japon] | Nicotinic receptor stimulation protects nigral dopaminergic neurons in rotenone‐induced Parkinson's disease models |
| 000A49 (2009) |
Payal N. Gandhi [États-Unis] ; Shu G. Chen [États-Unis] ; Amy L. Wilson-Delfosse [États-Unis] | Leucine‐rich repeat kinase 2 (LRRK2): A key player in the pathogenesis of Parkinson's disease |
| 000A59 (2009) |
Anna G Mez [Espagne] ; Isidre Ferrer [Espagne] | Increased oxidation of certain glycolysis and energy metabolism enzymes in the frontal cortex in Lewy body diseases |
| 000B82 (2009) |
Pablo Garrido-Gil [Espagne] ; Silvia Belzunegui [Espagne] ; Waldy San Sebastián [Espagne] ; Amaya Izal-Azcárate [Espagne] ; Berta L Pez [Espagne] ; Irene Marcilla [Espagne] ; Maria Rosario Luquin [Espagne] | 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine exposure fails to produce delayed degeneration of substantia nigra neurons in monkeys |
| 000C54 (2008) |
Payal N. Gandhi [États-Unis] ; Xinglong Wang [États-Unis] ; Xiongwei Zhu [États-Unis] ; Shu G. Chen [États-Unis] ; Amy L. Wilson-Delfosse [États-Unis] | The Roc domain of leucine‐rich repeat kinase 2 is sufficient for interaction with microtubules |
| 000C79 (2008) |
Genevieve Bureau [Canada] ; Fanny Longpré [Canada] ; M. Martinoli [Canada] | Resveratrol and quercetin, two natural polyphenols, reduce apoptotic neuronal cell death induced by neuroinflammation |
| 000D46 (2008) |
Yi Wei Lu [Singapour] ; Eng-King Tan [Singapour] | Molecular biology changes associated with LRRK2 mutations in Parkinson's disease |
| 000D81 (2008) |
Haiqun Jia [République populaire de Chine] ; Xin Li [République populaire de Chine] ; Hongxiang Gao [République populaire de Chine] ; Zhihui Feng [République populaire de Chine] ; Xuesen Li [République populaire de Chine] ; Lei Zhao [République populaire de Chine] ; Xu Jia [République populaire de Chine] ; Hongyu Zhang [République populaire de Chine] ; Jiankang Liu [États-Unis] | High doses of nicotinamide prevent oxidative mitochondrial dysfunction in a cellular model and improve motor deficit in a Drosophila model of Parkinson's disease |
| 000E15 (2008) |
Masaki Wakamatsu [Japon] ; Shingo Iwata [Japon] ; Takeo Funakoshi [Japon] ; Makoto Yoshimoto [Japon] | Dopamine receptor agonists reverse behavioral abnormalities of α‐synuclein transgenic mouse, a new model of Parkinson's disease |
| 000F72 (2007) |
Timothy M. Fountaine [Royaume-Uni] ; Richard Wade-Martins [Royaume-Uni] | RNA interference‐mediated knockdown of α‐synuclein protects human dopaminergic neuroblastoma cells from MPP+ toxicity and reduces dopamine transport |
| 000F75 (2007) |
I. Rite [Espagne] ; S. Argüelles [Espagne] ; J. L. Venero [Espagne] ; S. García-Rodriguez [Espagne] ; A. Ayala [Espagne] ; J. Cano [Espagne] ; A. Machado [Espagne] | Proteomic identification of biomarkers in the cerebrospinal fluid in a rat model of nigrostriatal dopaminergic degeneration |
| 000F97 (2007) |
Spiridon Papapetropoulos [États-Unis] ; Lina Shehadeh [États-Unis] ; Donald Mccorquodale [États-Unis] | Optimizing human post‐mortem brain tissue gene expression profiling in Parkinson's disease and other neurodegenerative disorders: From target “fishing” to translational breakthroughs |
